FDA Adverse Event Injury Summary report: N

TRULIANT TIB IMP CRC INSERT SZ 4, 15MM

MDR report key: 15324836 · Received August 30, 2022

Report

Report Number
1038671-2022-00972
Event Type
Injury
Date Received
August 30, 2022
Date of Event
July 21, 2022
Report Date
October 8, 2025
Manufacturer
EXACTECH, INC.
Product Code
JWH
UDI-DI
10885862307781
PMA / PMN Number
K152170
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

CONCOMITANTS MEDICAL DEVICES: 02-020-13-0340, TRULIANT CR CEM FEM CR CEM RIGHT SZ 4, K170240, (B)(4).

Additional Manufacturer Narrative · 0

D4: SERIAL AND EXPIRATION DATE CORRECTED. H4: MANUFACTURING DATE CORRECTED.

Description of Event or Problem · 0

IT WAS REPORTED VIA CLINICAL STUDIES, EXACTECH TRULIANT KNEE CLINICAL STUDY, THAT A 63 YO MALE PATIENT, 102 KG, WHO WAS INITIALLY IMPLANTED ON (B)(6) 2022, FOR THE PRIMARY DIAGNOSIS OF OSTEOARTHRITIS, REPORTED INCREASED PAIN IN THE CLINIC ON (B)(6) 2022. XRAYS SHOWED THE PATELLA TO BE HIGH-RIDING. SURGEON DETERMINED THE PATELLA TENDON HAD RUPTURED, AND REVISION SURGERY WAS PERFORMED ON (B)(6) 2022, 1 MONTH POST THE INITIAL PROCEDURE. THE PATIENT WAS REVISED WITH EXACTECH DEVICES. PATELLA TENDON REPAIRED. THE CASE REPORT INDICATES THE EVENT IS POSSIBLY RELATED TO THE PROCEDURE AND DEFINITELY NOT RELATED TO THE DEVICE. BASED ON REVIEW OF ALL AVAILABLE INFORMATION, THERE IS NO EVIDENCE TO SUGGEST THAT THE REPORTED EVENT IS RELATED TO ANY DESIGN OR MANUFACTURING ISSUES. THE CAUSE OF THE SUBSEQUENT REVISION CANNOT BE CONCLUSIVELY DETERMINED; HOWEVER, IT IS MOST LIKELY RELATED TO THE PATIENT¿S UNDERLYING CONDITIONS AND A RUPTURED PATELLA TENDON.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
314818 TRULIANT TIB IMP CRC INSERT SZ 4, 15MM PROSTHESIS, KNEE, PATELLOFEMOROTIBIAL, SEMI-CONSTRAINED, CEMENTED, JWH EXACTECH, INC. TRULIANT TIB IMP CRC INSERT SZ 4, 15MM UNK 10885862307781

Patients

Seq Age Sex Outcome Treatment
1 63 YR Male Hospitalization| R SEE H10.